Beijing Tiantan Biological Products (600161) H1 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 reached ¥3.11 billion, up 9.47% year-over-year, driven by higher sales volume.

• Net profit attributable to shareholders was ¥632.56 million, down 12.88% year-over-year due to lower product prices and reduced interest income.

• Gross margin for biopharmaceuticals was 45.31%, with human albumin and IVIG as key contributors.

• The company maintained its leading domestic position in blood products, with 85 operating plasma stations and a 20% market share in plasma collection.

• R&D investment remained high, with new product approvals, clinical trials advancing, and two new patents granted.

Financial highlights

• Operating income: ¥3.11 billion, up 9.47% year-over-year.

• Net profit attributable to shareholders: ¥632.56 million, down 12.88% year-over-year.

• Basic and diluted EPS: ¥0.32, down from ¥0.37 in the prior year period.

• Net cash flow from operating activities: -¥201.90 million, compared to ¥1.21 billion last year.

• Total assets at period end were ¥16.52 billion, up 4.11% from the start of the year.

Outlook and guidance

• The company expects continued growth in blood product demand, especially for immunoglobulin and coagulation factors.

• Ongoing expansion of production capacity with new facilities in Yunnan and Lanzhou to enhance scale and efficiency.

• Focus on innovation, digital transformation, and international market expansion.

• No uncertainties affecting the accuracy of the performance report were identified.